​奥希替尼(Osimertinib)

Osimertinib is a kinase inhibitor indicated for the treatment of patients with a specific type of lung cancer (metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC))1,2,3:

-As first-line treatment of patients whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test1.

-As second line treatment of patients whose disease has progressed on or after EGFR TKI therapy1,2,3.